A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol. [electronic resource]
Producer: 20160108Description: 78 p. digitalISSN:- 1471-2407
- Breast Neoplasms -- drug therapy
- Camptothecin -- administration & dosage
- DNA Topoisomerases, Type I -- genetics
- Drug Administration Schedule
- Female
- Gene Dosage
- Genetic Markers -- genetics
- Humans
- Irinotecan
- Neoplasm Metastasis
- Prospective Studies
- Receptor, ErbB-2 -- genetics
- Topoisomerase I Inhibitors -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.